小剂量利培酮治疗首发精神分裂症临床研究

An open clinical study on treatment of lower - dose risperidone in firstepisode patients with schizophrenia

目的 探讨小剂量利培酮对首发精神分裂症的有效性、安全性、可行性。方法 对符合CCMD-2-R诊断、病程≤1年、首次住院治疗的分裂症各型男女各30例病人,进行利培酮≤2mg/d 12周治疗,以PANSS、GAS、CGI评定疗效,TESS、ESRS评定副作用。结果 脱落率为1.67％,有效率96.61％,显效率62.71％,起始剂量79.66％≤1mg/d,最大2mg/d。1周起效率35.59％,治疗量78％≤2mg/d。EPS发生率16.95％,程度轻,大部不需处理。结论 小剂量利培酮治疗首发分裂症,有效性好、安全性高、可行性强。

Objective To explore the clinical efficacy, safety and feasibility of treatment of lower - dose risperidone in first - episode schizophrenic patients. Methods Sixty first - episode schizophrenic inpatients with courses of less than 1 year were treated with lower - dose risperidone ( ≤ 2mg/d) for 12 weeks. All subjects met the Chinese Classification and Diagnostic Criteria for Mental Disorders, 2nd edition, re vised (CCMD - 2 - R) criteria for schizophrenia. Efficacy results were assessed by Positive And Negative Syndrome Scale, Global Assessment Scale, Clinical Global Impression scale and side effects by Treatment Emergent Symptom Scale, Extrapyramidal Symptom Rating Scale. Results Of the 60 patients, one (1.67%) was dropout. Fifty - seven (96.61%) were improved while 62.71% significantly improved.The initial doses of risperidone were 0.5 to 2mg per day,but 79.66% were Img/d or lower. Most patients were improved in the first therapy - week and 78 % with the target doses of 2mg/d or lower. Extrapyramidal symptoms were observed in 16.78 % of the subjects, but most were too mild to be dealt with. Conclusions It was effective, safe and feasible to treat first -episode schizophrenic patients with lower - dose risperidone.